Vaxart, Inc. (VXRT)
NASDAQ: VXRT · Real-Time Price · USD
0.3400
-0.0089 (-2.55%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Vaxart Revenue
In the year 2024, Vaxart had annual revenue of $28.70M with 288.94% growth. Vaxart had revenue of $15.19M in the quarter ending December 31, 2024, with 367.95% growth.
Revenue (ttm)
$28.70M
Revenue Growth
+288.94%
P/S Ratio
2.42
Revenue / Employee
$273,333
Employees
105
Market Cap
78.39M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.70M | 21.32M | 288.94% |
Dec 31, 2023 | 7.38M | 7.27M | 6,796.26% |
Dec 31, 2022 | 107.00K | -785.00K | -88.00% |
Dec 31, 2021 | 892.00K | -3.15M | -77.95% |
Dec 31, 2020 | 4.05M | -5.82M | -58.97% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
VXRT News
- 2 days ago - Vaxart to Present at World Vaccine Congress Washington 2025 on April 23 - GlobeNewsWire
- 2 days ago - Vaxartto Present at World Vaccine Congress Washington 2025 on April 23 - GlobeNewsWire
- 22 days ago - Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Vaxart, Inc. (VXRT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Vaxart Provides Business Update and Reports Full Year 2024 Financial Results - GlobeNewsWire
- 5 weeks ago - Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate - GlobeNewsWire
- 6 weeks ago - Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults - GlobeNewsWire
- 3 months ago - Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial - GlobeNewsWire